PASSIGLIA, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 2.266
EU - Europa 1.303
AS - Asia 645
AF - Africa 15
SA - Sud America 7
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.243
Nazione #
US - Stati Uniti d'America 2.239
IT - Italia 420
IE - Irlanda 355
CN - Cina 331
SE - Svezia 168
VN - Vietnam 96
GB - Regno Unito 65
FR - Francia 64
UA - Ucraina 58
HK - Hong Kong 49
KR - Corea 38
DE - Germania 32
PL - Polonia 32
IN - India 30
SG - Singapore 23
CA - Canada 21
NL - Olanda 20
JP - Giappone 17
ES - Italia 14
JO - Giordania 12
DK - Danimarca 9
BE - Belgio 8
CH - Svizzera 8
FI - Finlandia 8
TW - Taiwan 8
MY - Malesia 7
PK - Pakistan 7
BA - Bosnia-Erzegovina 6
GR - Grecia 6
NG - Nigeria 6
RO - Romania 6
TR - Turchia 6
EG - Egitto 5
IR - Iran 5
MX - Messico 5
RU - Federazione Russa 5
AU - Australia 4
CL - Cile 4
RS - Serbia 4
SI - Slovenia 4
TH - Thailandia 4
PS - Palestinian Territory 3
SA - Arabia Saudita 3
ZA - Sudafrica 3
AP - ???statistics.table.value.countryCode.AP??? 2
AT - Austria 2
ID - Indonesia 2
ME - Montenegro 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
AM - Armenia 1
AR - Argentina 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
IL - Israele 1
JM - Giamaica 1
MC - Monaco 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.243
Città #
Dublin 353
Chandler 298
Fairfield 261
Beijing 134
Houston 119
Nyköping 118
Ashburn 115
Wilmington 111
Seattle 108
Medford 104
Woodbridge 98
Princeton 86
Torino 85
Turin 77
Cambridge 73
Dong Ket 71
Jacksonville 45
Hangzhou 38
Ann Arbor 35
Pisa 34
Warsaw 27
Dearborn 24
Seoul 23
Milan 20
San Diego 19
Hebei 18
Central 17
Central District 17
New York 17
Amsterdam 16
Shanghai 15
Nanjing 13
Norwalk 13
Amman 12
Guangzhou 12
London 12
Paris 11
Piemonte 11
Redwood City 11
Chengdu 9
Rome 9
Boston 8
Brussels 8
Hefei 8
Tokyo 7
Abuja 6
Banja Luka 6
Helsinki 6
Hong Kong 6
Karachi 6
Preveza 6
San Mateo 6
Toronto 6
Chaponost 5
Fuzhou 5
Guiyang 5
Kunming 5
Madrid 5
Mumbai 5
New Delhi 5
Upper Marlboro 5
Belgrade 4
Brookline 4
Castellaneta 4
Chennai 4
Duncan 4
Falls Church 4
Genoa 4
Manchester 4
Newcastle upon Tyne 4
Pittsburgh 4
Preston 4
Redmond 4
San Francisco 4
Santiago 4
Taipei 4
Tanjong Malim 4
Washington 4
Atlanta 3
Bengaluru 3
Chongqing 3
Coyoacán 3
Edinburgh 3
Fremont 3
Genay 3
Hyderabad 3
Johannesburg 3
Kuala Lumpur 3
Los Angeles 3
Luni 3
Montréal 3
Padova 3
Philadelphia 3
Phoenixville 3
Ramallah 3
Riverton 3
San Jose 3
Shenzhen 3
Singapore 3
Stockholm 3
Totale 2.942
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 241
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 166
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 111
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 102
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 96
Multisciplinary management of patients with liver metastasis from colorectal cancer 87
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 87
Improving lung cancer outcomes through smoking cessation: The women against lung cancer in Europe (WALCE) experience 86
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 85
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 83
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 81
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 81
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? 74
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 74
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 72
Nintedanib in NSCLC: Evidence to date and place in therapy 72
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 68
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 68
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 68
Circulating programmed death ligand-1 (cPD-L1) in non-small- cell lung cancer (NSCLC) 67
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 67
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review 67
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 65
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 63
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 62
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 61
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves 61
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? 61
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 61
Lung Cancer in Italy 54
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 54
Repositioning PARP inhibitors in the treatment of thoracic malignancies 54
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… 53
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle? 52
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 47
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 47
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 47
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 46
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer 44
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 42
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 42
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy 42
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 41
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 40
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 40
Cancer and the microbiome: Potential applications as new tumor biomarker 39
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery 39
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 38
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 37
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 36
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small-cell lung cancer?. 36
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: Focus on steroids and autoimmune disease 35
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations 34
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 33
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment 33
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 33
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 32
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients? 31
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 30
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 29
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going? 28
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 27
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 26
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All? 25
The evolving paradigm of precision medicine in lung cancer 25
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 23
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 22
The role of targeted therapy for gastrointestinal tumors 21
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 21
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 21
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib 20
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 20
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 19
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 19
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy 18
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 18
EGFR inhibition in NSCLC: New findings…. and opened questions? 18
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 18
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 18
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 17
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 17
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer 16
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 16
Ramucirumab and its use in gastric cancer treatment 16
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 16
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial 15
Winds From the ORIENT: New Data to Inform RATIONAL Choice? 15
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC 14
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 14
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 14
The role of germline mutations in thoracic malignancies: between myth and reality 13
Liquid biopsies in lung cancer: The new ambrosia of researchers 13
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice 12
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 12
Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians 11
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 11
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies 10
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun 10
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups 10
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes 8
Totale 4.384
Categoria #
all - tutte 16.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.014

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019227 0 0 0 0 0 0 0 77 44 1 99 6
2019/2020525 6 3 12 57 8 35 53 77 79 81 79 35
2020/2021835 24 46 102 34 79 77 34 59 79 95 50 156
2021/2022957 68 48 50 43 59 39 79 57 42 63 240 169
2022/20231.395 111 115 32 95 101 369 147 89 163 40 81 52
2023/2024490 100 137 36 69 36 47 32 33 0 0 0 0
Totale 4.429